Should You Buy BioMarin Pharmaceutical Before Feb. 18? [Yahoo! Finance]
BioMarin Pharmaceutical Inc. (BMRN)
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.biomarin.com
Company Research
Source: Yahoo! Finance
The drugmaker will almost certainly report its 2025 full-year and fourth-quarter results in the coming weeks. Last year, BioMarin provided its Q4 update on the third Wednesday in February. The company could choose the same day this year. If it does, investors may want to circle Feb. 18, 2026, on their calendars. But should you buy the biotech stock before then? Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks » One reason to consider buying BioMarin before its Q4 results are announced is that rare-disease drug Voxzogo is expected to have a strong quarter. CFO Brian Mueller said in the company's Q3 earnings call that Voxzogo revenue should "reach its highest level of the year" in Q4. The primary concern for most investors when buying a stock before a quarterly earnings announcement is the possibility that the company will fall short of Wall Street's estimates.
Show less
Read more
Impact Snapshot
Event Time:
BMRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMRN alerts
High impacting BioMarin Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
BMRN
News
- BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target lowered by analysts at Piper Sandler from $122.00 to $84.00. They now have an "overweight" rating on the stock.MarketBeat
- Jefferies Downgrades Amicus Therapeutics, Inc. (FOLD) to Buy And Lowers Price Target Amid Takeover Developments [Yahoo! Finance]Yahoo! Finance
- BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan FacilityPR Newswire
- BioMarin's Amicus Deal Funding Reshapes Debt Load And Rare Disease Reach [Yahoo! Finance]Yahoo! Finance
- BioMarin Pharmaceutical (NASDAQ:BMRN) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $80.00 price target on the stock.MarketBeat
BMRN
Earnings
- 10/27/25 - Miss
BMRN
Sec Filings
- 1/29/26 - Form 8-K
- 1/26/26 - Form 8-K
- 1/22/26 - Form 4
- BMRN's page on the SEC website